Sio Gene Therapies Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Sio Gene Therapies Inc. (SIOX) operates as a clinical-stage biopharmaceutical company focused on developing gene therapies for neurodegenerative diseases, including Parkinson's disease, GM1 gangliosidosis, and GM2 gangliosidosis (Tay-Sachs and Sandhoff diseases); its pipeline features AAV-based candidates such as AXO-AAV-GM1 for GM1 gangliosidosis, AXO-AAV-GM2 for GM2 gangliosidosis, and AXO-Lenti-PD for Parkinson's disease. The company maintains license agreements with Oxford BioMedica (UK) Ltd. for AXO-Lenti-PD and related products and with The University of Massachusetts Medical School for AXO-AAV-GM1 and AXO-AAV-GM2. Founded in October 2014 as a subsidiary of Roivant Sciences and formerly known as Axovant Gene Therapies Ltd. (name changed in November 2020), Sio Gene Therapies maintains headquarters in New York City and previously operated from Basel, Switzerland. Sio Gene Therapies targets rare pediatric and adult neurological disorders with no approved curative therapies, conducting clinical trials primarily in the United States and Europe through contract manufacturing partners like Yposkesi. In April 2022, the company terminated its licensing agreement for the AXO-Lenti-PD program from Oxford BioMedica due to resource requirements and development timelines, prioritizing the GM1 and GM2 programs while significantly reducing its workforce to conserve cash. By December 2022, its board approved a plan of complete liquidation and dissolution following evaluation of strategic alternatives, culminating in shareholder approval on April 5, 2023, completion of foreign subsidiary dissolutions in January 2024, and filing for dissolution with an initial liquidating distribution of $0.435 per share.
Sio Gene Therapies, Inc. to File for Dissolution and Declare an Initial Liquidating Distribution of $0.435 Per Share
Penny Stocks To Buy Now? 10 Stocks Under $1 To Watch
3 Hot Penny Stocks To Buy For Under $1 Right Now
Sio Gene Therapies Ditches Two Remaining Programs, Seeks Buyer(s), Shares Plunge
Sio Gene Therapies to Present at the 18th Annual WORLDSymposium™ 2022
Sio Gene Terminates Parkinson's Gene Therapy Pact With Oxford Biomedica, Announces CEO Transition
My Favorite Stock For 2022: Sio Gene Therapies
Sio Gene Therapies: Risk-On Gene Therapy Prospect May Offer Value For Money
Sio Gene Therapies: Excellent Data And News Obscured By Officer's Departure
Top Penny Stocks to Buy Now? 3 Under $4 to Watch
SIOX Stock: Why It Increased Today
3 ‘Must Watch' Penny Stocks For Your Watchlist Right Now
UPDATE: Sio Gene Therapies to Present New Data at the European Society of Gene and Cell Therapy Virtual Congress 2021
Sio Gene Therapies to Present New Data at the European Society of Gene and Cell Therapy Virtual Congress 2021
Sio Gene Therapies to Participate in Upcoming Conferences
Sio Gene Therapies Announces Dosing of First GM1 Gangliosidosis Early Infantile (Type I) Patient in Ongoing Phase 1/2 Study of AXO-AAV-GM1 Gene Therapy
Week 26 MDA Breakout Stocks - July 2021: Short-Term Picks To Give You An Edge
SIOX Stock Price Increases Over 15% Pre-Market: Why It Happened
Sio Gene Therapies Announces Fiscal Year 2020 Year-End Financial Results and Expected Fiscal Year 2021 Key Milestones
Sio Gene Therapies: Gene Therapies For Neurodegeneration